Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study

Sorafenib is the only Food and Drug Administration (FDA)-approved first-line therapy shown to have survival benefit for patients with advanced hepatocellular carcinoma (HCC). Patients with advanced HCC are often but not exclusively transferred from non-oncologists to oncologists to initiate systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, David E., Mehta, Rajni, D’Addeo, Kathryn, Valderrama, Adriana, Taddei, Tamar H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794408/
https://www.ncbi.nlm.nih.gov/pubmed/29369224
http://dx.doi.org/10.1097/MD.0000000000009757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794408/
https://www.ncbi.nlm.nih.gov/pubmed/29369224
http://dx.doi.org/10.1097/MD.0000000000009757

Ejemplares similares